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Objectives: Our objective was to obtain international consensus on 
a set of core outcome measures that should be recorded in all clin-
ical trials of interventions intended to modify the duration of ventila-
tion for invasively mechanically ventilated patients in the ICU.
Design: A two-stage consensus process was undertaken be-
tween December 2015 and January 2018. Stage 1 included an 
online three-round Delphi study and three consensus meetings. 
Stage 2 included three consensus meetings.
Setting: The setting was international, including Europe, North 
and South America, Australia, Asia, and Africa.
Participants: Organization members representing intensive care 
survivors and carers; nursing, allied health professionals, and crit-
ical care physicians; clinical trials groups and trial investigators; and 
industry.
Interventions: None.
Measurements and Main Results: Delphi study outcomes were 
scored by participants from one (least important) to nine (most 
important). Consensus criteria for including the outcome in the 
core set were more than 70% of responses rating the outcome 
above seven and not more than 15% rating the outcome less 
than 3. From 222 participants, 183 from 38 organizations in 
27 countries contributed to the consensus process. Stage 1: 
Delphi response rates from 200 participants ranged from 89% 
to 90% across three rounds. Forty-seven outcomes were ranked 
as follows: 19 met consensus criteria for inclusion and were 
considered at three consensus meetings (33 participants). Six 
outcomes were agreed for the core set as follows: extubation, 
reintubation, duration of mechanical ventilation, length of stay, 
health-related quality of life, and mortality. Stage 2: Three con-
sensus meetings (37 participants) agreed on the measures for 
each outcome.
Conclusions: We used rigorous and well-established methods 
to develop a core outcome set for use in all clinical trials evalu-
ating interventions intended to modify duration of mechanical 
ventilation. This core outcome set will inform the design of fu-
ture trials in this field by strengthening methodological quality 
and improving comparability across trials. (Crit Care Med 2019; 
XX:00–00)
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Clinical trials provide evidence for best clinical practice, but comparisons of findings across trials are difficult because of differences in the selection and reporting 
of trial outcomes. The resulting inability to compare find-
ings not only diminishes our ability to synthesize evidence 
and address knowledge gaps but wastes research resources (1). 
Several Cochrane Reviews of trials evaluating ventilator wean-
ing protocols spanning 2 decades have highlighted substantial 
variation in outcome selection, definition, measurement, and 
reporting (2–4). More recently, we (B.B., M.C., J.C.M., L.R., 
D.F.M.) have shown in a review of 66 trials that inconsistency 
in ventilation outcome reporting in critical care trials remains 
problematic: among the 66 trials, only 12 (25%) provided a 
definition and 16 different definitions of duration of mechan-
ical ventilation were used (5). Ideally, trials focused on the 
same health condition and intervention should assess the same 
clinically meaningful outcomes and measure them in a similar 
fashion to facilitate more appropriate comparisons.
Standardization in selection and measurement of a core 
outcome set (COS) has been proposed as a method of address-
ing problems of inconsistency. A COS is defined as the min-
imum set of outcomes that should be measured and reported 
in all clinical trials of a specific condition (6). Using a COS 
ensures that trials collect the same outcomes in standard ways, 
which increases availability of the most important and relevant 
information for meta-analyses. The Core Outcome Measures 
in Effectiveness Trials (COMET) initiative, a resource repos-
itory for COS researchers and users, summarizes the current 
methodological approach for COS development (7). The rec-
ommended multistage process advocates obtaining consensus 
on “what” outcomes should be in the COS, before addressing 
“how” and “when” these outcomes should be measured (7). 
Within critical care, the effort to drive COS development for-
ward is championed by the International Forum for Acute Care 
Trialists (InFACT) and is receiving widespread attention by the 
critical care research community (8). COS for cardiac arrest 
(9) and long-term outcomes in acute respiratory failure are al-
ready completed (10), with others relating to physical rehabili-
tation (11), delirium (12), and subarachnoid hemorrhage (13) 
are at different stages of development.
We sought to develop a COS for trials testing any interven-
tion intended to modify mechanical ventilation duration in 
critical care. In recognizing that trial outcomes should include 
health results most relevant to patients, our specific objectives 
were to engage relevant participants in identifying important 
core outcomes for these trials and to obtain agreement on how 
they should be defined, measured, and reported. This COS is 
intended for use in randomized trials of interventions for inva-
sively mechanically ventilated adults in critical care, but would 
also be suitable for nonrandomized studies.
MATERIALS AND METHODS
This Core Outcomes in Ventilation Trials (COVenT) study 
used a two-stage, mixed methods, consensus approach (Fig. 1). 
COVenT Stage I determined “what” outcomes to include. 
COVenT Stage II determined “how” the agreed outcomes 
should be measured. Methods included systematic reviews of 
published (5), unpublished (J Friedrich and J Marshall, InFACT 
February 29, 2016, personal communication); Ringrow et al 
(14) and online information sources (Improve Long-Term 
Outcome COS www.improvelto.com); a three-round, online 
Delphi study supported by a bespoke e-management system 
(DelphiManager, Version 1.0 2014, University of Liverpool, 
United Kingdom); webinar and face-to-face consensus meet-
ings. For more details on methods, see eAppendix 1 and eAp-
pendix 2 for the Delphi questionnaire (Supplemental Digital 
Content 1, http://links.lww.com/CCM/E744).
To recruit Delphi participants, we contacted a broad range 
of international organizations representing: ICU survivor 
and carer support groups; nursing, allied health professional 
(AHP), and medical critical care societies; critical care clin-
ical trials groups and trial investigators; and industries in-
volved with ventilation equipment. Organization leads either 
notified members about the study for self-selection or identi-
fied member representatives. Consensus meeting participants 
were recruited from Delphi respondents completing all three 
rounds. Additionally, we purposively invited a cohort of non-
Delphi participants, including a statistician, health econo-
mist, two critical care journal, and social media editors and 
others to provide specific methodological expertise. Names 
and affiliations of COVenT participants are listed in eAppen-
dix 3 (Supplemental Digital Content 1, http://links.lww.com/
CCM/E744).
COVenT was registered on the COMET database, and the 
study protocol was published (15, 16). The COVenT study 
was ethically approved by Queen’s University Belfast, School 
of Medicine Ethics Committee (reference: 14.34v2; October 3, 
2014). Findings are reported according to accepted standards 
for reporting COS development (17).
RESULTS
In total, 222 participants were recruited and 183 contributed 
to the final consensus process. The final 183 included 161 par-
ticipants that completed all three rounds of the Delphi study 
and an additional 22 non-Delphi participants. Table 1 shows 
the stakeholder composition and geographical spread of the 
183 participants.
COVenT Stage I Results
The Delphi study was conducted from December 2015 to 
March 2016 and 200 participants participated in round one. 
Subsequently, 178 of 200 (89%) completed round two and 
161 of 178 (90%) completed round three (Fig. 1). The propor-
tions of panel participants were 9% ICU survivors/carers; 50% 
nurses, AHP, and physicians; 35% trials group members and 
investigators; and 6% industry. Participant stakeholder groups 
and geographical locations are shown in eTable 1 (Supple-
mental Digital Content 1, http://links.lww.com/CCM/E744).
Round one contained 24 outcomes and Delphi par-
ticipants recommended 23 additional outcomes that were 
added to round two (47 outcomes in total) (see eAppendix 
2 for the questionnaire, Supplemental Digital Content 1, 
Clinical Investigation
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http://links.lww.com/CCM/E744). After round three, 19 
outcomes met consensus criteria (> 70% participants scor-
ing the outcome as critical and not more than 15% rating 
the outcome not critical). We classified outcomes using the 
COMET taxonomy structure into categories of death; phys-
iologic/clinical; life impact; resource use; and adverse events 
(18) (eTable 2, Supplemental Digital Content 1, http://links.
lww.com/CCM/E744). The research team (authors) con-
sidered the taxonomy and noted overlapping similarities in 
outcomes within categories (e.g., mortality and survival). 
Furthermore, 19 outcomes were considered too large for a 
COS; therefore, these were taken forward for further discus-
sion and voting “in,” “out,” or “unsure” at three consensus 
meetings: two webinar meetings (October 11, 2016, and 
October 17, 2016; n = 33 participants); and a follow-up tel-
econference with ICU survivors and family carers (October 
25, 2016; n = 4). Webinar voting details are presented in eTa-
bles 3 and 4 (Supplemental Digital Content 1, http://links.
lww.com/CCM/E744).
From the consensus meetings, nine outcomes were voted in as 
“core” (Table 2), but only six were universally agreed by all. These 
six form the COS are as follows: extubation, reintubation, duration 
of mechanical ventilation, length of stay, health-related quality of 
life (HRQOL), and mortality. The three outcomes not universally 
agreed were survival, pulmonary complications, and delirium.
COVenT Stage II Results
We convened two webinar 
meetings (November 13, 2017, 
and November 17, 2017) and a 
face-to-face meeting (February 
6, 2018) including 37 partici-
pants to determine definitions 
and measures for the six core 
outcomes. At the meetings we 
presented a set of preliminary 
definitions and measures de-
rived from the aforementioned 
systematic reviews and based 
on four recommended compo-
nents for defining an outcome 
(specific variable, analysis 
metric, aggregation method, 
and time point) (19) (prelim-
inary list detailed in eTable 5, 
Supplemental Digital Content 
1, http://links.lww.com/CCM/
E744). Consensus was gained 
through discussion and voting. 
Webinar participants reached 
agreement on definitions and 
measures for four outcomes 
(duration of mechanical venti-
lation, length of stay, HRQOL, 
and mortality), but did not 
reach consensus on two (extu-
bation and reintubation). The 
remaining two outcomes were discussed and agreed in the final 
face-to-face meeting (eTable 5, Supplemental Digital Content 
1, http://links.lww.com/CCM/E744).
Table 3 presents the final core outcome measurement set 
detailing how the outcomes should be specifically defined and 
measured and, where necessary, provides additional clarifica-
tion and recommendations. Table 4 details the study variable 
fields that investigators can insert into an electronic case report 
form for a clinical trial.
DISCUSSION
This large, international consensus study, including partici-
pants from 38 organizations in 27 countries has established a 
COS for critical care trials of interventions intended to modify 
mechanical ventilation duration. The six core outcomes are 
extubation, reintubation, duration of mechanical ventilation, 
length of stay, HRQOL, and mortality. Additionally, this study 
provides the specific measurement variable; analysis metric; 
aggregation method; and measurement time-point for each 
outcome. All outcome data should be reported for survivors 
and, where appropriate, nonsurvivors. This COS represents 
the minimum number of outcomes. Additional outcomes and 
measurement time points can be added at the investigators’ 
discretion. To our knowledge, this study is the first to develop 
Figure 1. Core Outcomes in Ventilation Trials study flow diagram.
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a COS for ventilation trials, as such, this represents important 
new insight for critical care investigators.
The validity of this COS is strengthened by following a 
robust development process, including a Delphi study and 
consensus meetings that enabled wide representation and 
engagement. The sample size for consensus processes is 
not determined by achieving statistical power, rather the 
main consideration is maximizing representation from key 
stakeholder groups (7). We achieved this through broad ge-
ographical and stakeholder composition. The importance 
of a wide stakeholder group in COS development is not to 
be underestimated in achieving agreement on outcomes 
that are relevant and important to patients, clinicians, and 
researchers.
Duration of mechanical ventilation and length of stay out-
comes relate to successful medical management and prompt 
liberation from mechanical ventilation. Although they are 
commonly used in ventilation trials, they are inconsistently 
defined and measured (5); therefore, their appearance in the 
COS was not unexpected. Likewise, extubation and reintuba-
tion, while less frequently measured in trials (20), influence 
ventilation duration and length of stay and thus require clini-
cally meaningful definitions. Conversely, outcomes important 
to patients, such as HRQOL are not generally profiled in trials. 
Indeed, a recent systematic review of critical care trials found 
only 22% (160/713) reported patient-important outcomes 
with HRQOL accounting for only 3% (n = 22 trials) (20). The 
inclusion of less commonly reported, but nevertheless, clearly 
important outcomes in the COS serves to show the value of 
engaging patients in COS development.
This COS defines randomization as the measurement start 
point for the time-related outcomes, duration of mechanical 
ventilation, and length of stay. Participants considered ran-
domization a more reliable start point as it marks commencing 
delivery of the experimental or control intervention to modify 
an outcome. However, for research designs where randomiza-
tion does not signal commencement of intervention delivery, 
the COS recommends that alternative start point should be 
clearly justified and defined.
The recommended endpoint for extubation and duration 
of mechanical ventilation is defined as “successful extubation” 
and “unassisted breathing,” respectively, at 48 hours. A pre-
vious round table conference on weaning defined 48 hours as 
the time-point measure of success, but this is now more than 
10 years old (21). In the light of newer practices incorporat-
ing noninvasive ventilation as a weaning strategy or to treat 
post extubation respiratory distress, arguably identification 
of success of extubation should be at a more distal time-point 
(22). However, although there is no evidence for adopting the 
48-hour period to define success, in the current study, partici-
pant expert opinion upheld 48 hours because any subsequent 
need for intubation and ventilation would likely be related to 
TABLE 2. Outcomes Agreed at Each 
Consensus Meeting and the Final Core 
Outcome Set (Bold)
Webinar 1 Webinar 2 Teleconference
Outcomes agreed and reaching consensus by all three meeting 
groups
 Successful 
extubation
Successful  
extubation
Successful  
extubation
 Reintubation Reintubation Reintubation
 Duration IMV Duration IMV Duration IMV
 LOS (hospital) LOS (ICU) LOS (hospital)
 HRQOL HRQOL HRQOL
 Mortality Mortality Mortality
Outcomes agreed and reaching consensus by one or  
two meeting groups
 Survival Survival
 Pulmonary 
complications
 Pulmonary compli-
cations
  Delirium
n = 7 n = 7 n = 9
HRQOL = health-related quality of life, IMV = invasive mechanical ventilation, 
LOS = length of stay.
LOS was retained as a core outcome for consideration of the measurement 
time point in Core Outcomes in Ventilation Trials stage II.
TABLE 1. Characteristics of Core Outcomes 
in Ventilation Trials Participants
Composition n (%)
Stakeholder
 Clinicians 82 (45)
 Researchers 76 (41.5)
 ICU survivors/carers 15 (8)
 Industry 10 (5.5)
Geographical
 Europe 116 (63)
  United Kingdom (52), Ireland (3), Germany 
(4), Italy (7), Spain (3), Greece (6), 
Sweden (6), Israel (1), Netherlands (4), 
France (5), Turkey (5), Austria (3), Malta 
(1), Slovenia (3), Poland (4), Croatia (1), 
Switzerland (7), Belarus (1)
 
 North America 45 (25)
  United States (31), Canada (14)  
 Australasia 15 (8)
  Australia (13), New Zealand (2)  
 Asia 3 (2)
  Singapore (1), India (1), Philippines (1)  
 South Africa 3 (2)
 South America (Brazil) 1 (1)
Clinical Investigation
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a new clinical event. Additionally, the endpoint for duration of 
mechanical ventilation, “unassisted breathing,” is defined as a 
patient being free from invasive ventilation, including extra-
corporeal lung support and noninvasive ventilation delivering 
volume or pressure support. Although we recognize that con-
tinuous positive airway pressure and high-flow oxygen therapy 
may not be truly “unassisted,” these modes of ventilation were 
excluded from the definition of assisted breathing. Further, 
high-flow oxygen therapy devices technically only modify per-
centage of oxygen delivery and rate of gas flow rather than as-
sisted support as provided by the other forms of mechanical 
ventilation (23).
TABLE 3. Final Core Outcome Measurement Set for All Clinical Trials Evaluating 
Interventions Intended to Modify Duration of Mechanical Ventilation
Extubation
 Definition: Time from randomization to first successful extubation.
 Measurement: Mean and median time (hr) to establishment of natural airway (meaning all tube extubation) with a follow-up to 60 
d from randomization (censor at hospital discharge).
 Clarifications: Extubation is defined as free from all tubes, endotracheal tube, and tracheostomy. Success is defined as remaining 
free from tubes at 48 hr. Time does not include the 48-hr success period. If discharged from hospital before the 48-hr success 
period, assume extubation is successful.
Reintubation
 Definition: Reintubation of endotracheal tube after an extubation that was planned.
 Measurement: All reintubation events with date/time. Report as total number of reintubations after a planned extubation in 
each group and the average number of reintubation events/patient in each group. Time to follow-up 60 d from randomization 
(censor at hospital discharge).
 Clarifications: Excludes “reinsertion for procedure only,” i.e., temporary elective reintubations.
Duration of mechanical ventilation
 Definition: Time from randomization until first successful unassisted breathing or death.
 Measurement: Mean and median time (hr). Follow-up to 60 d from randomization (censor at hospital discharge).
 Clarifications: Unassisted breathing defined as no inspiratory support or extracorporeal lung support. Success defined as 
remaining to breathe unassisted at 48 hr. Measure time by calculating date/time of start and stop; do not include the 48-
hr success period. Record date/time of all periods of ventilation up to day 60. Present data for survivors and nonsurvivors. 
Duration includes time receiving extracorporeal lung support, invasive mechanical ventilation and noninvasive ventilation 
delivering volume or pressure support ventilation; excludes high-flow oxygen therapy and continuous positive airway pressure.
Duration of stay
 Definition: Time from randomization until patient first leaves the relevant facility or death.
 Measurement: Mean and median time (hr). Follow-up to 60 d from randomization (censor at discharge).
 Clarifications: Can include “critical care length of stay,” “hospital length of stay,” or both. Define censoring points. “Hospital” and 
“critical care” must be clearly defined a priori in the study protocol. Definition should ideally include information on country, type 
of hospital, type of ICU (open/closed model), ICU staff to patient ratios, payment system, and access to long-term ventilator 
facilities.
Mortality
 Definition: Confirmation of death.
 Measurement: Number of events in each group reported as the mortality rate. Follow-up to 60 d from randomization.
 Recommendation: Recording date/time of randomization and death will enable survival analysis to be undertaken (if required).
Health-related quality of life
 Definition: EQ-5D-5L as a quality of life tool.
 Measurement: Distribution of responses for each dimension level reported as the number and % of responses and the mean 
visual analog scale score. Follow-up to 6 mo from randomization.
 Clarification: EQ-5D-5L should be reported as the distribution of responses rather than a health utility score.
EQ-5D-5L = EuroQol 5 dimensions 5 levels.
General recommendations: Report all outcome data for survivors and, where appropriate, nonsurvivors. This core outcome set represents the minimum 
number of outcomes. Additional outcomes and measurement time points can be added at the investigators’ discretion.
Blackwood et al
6 www.ccmjournal.org XXX 2019 • Volume XX • Number XXX
Participants recognized that achieving standardized meas-
ures of length of stay was challenging due to international 
differences in healthcare provision. Length of stay is generally 
used as a benchmark to assess healthcare systems, with shorter 
stays typically associated with system efficiency (24) and for 
this reason, it was deemed important for the COS. Although 
length of stay may reflect important progress in a patient’s tra-
jectory of recovery, structural and process factors may impact 
its standardization. The average length of stay, in both ICU and 
hospital, varies considerably between countries, with nonclin-
ical factors, such as professional or cultural settings, differing 
public and private healthcare reimbursement schemes, and 
access to long-term care and ventilator facilities contributing to 
international variability (25, 26). Given the influence of these 
factors on duration of stay and challenges in modifying them, 
the COS recommends that investigators clearly define the set-
ting (hospital and/or critical care facility) and any censoring 
points in their study protocol to facilitate understanding of 
comparisons and generalizability.
The reported mortality endpoint in critical care trials has 
varied from 28 to 90 days and, in some trials, up to 1 year (5). 
In selecting a pragmatic mortality time-point for the COS, 
participants considered a number of important reasons for 
agreeing on 60 days. First, measuring ICU and hospital mor-
tality was considered limiting due to potential variability in 
duration of stay as a result of factors unrelated to the patient’s 
condition. Second, the time-point should be stable and realis-
tically capture the full effects of the intervention. Although a 
short time-point (e.g., 28 d) might capture immediate survival 
impact, the mortality rate could be manipulated by delaying 
clinical decisions (e.g., withdrawal of treatment); therefore, 
participants considered a more distal time-point preferable. 
The 60-day choice was informed by a systematic review of trials 
reporting mortality at three or more time-points that showed 
significant incremental risk difference between treatment 
arms to at least 60 days after randomization (J. Friedrich and 
J. Marshall, personal communication, 2016). A third reason for 
choosing 60 days was that the time-point should not substan-
tially increase the burden of follow-up.
Defining the HRQOL outcome measure was greatly assisted 
because the Improve Long-Term Outcome group had already 
completed a COS that included HRQOL measures. The group 
recommended the EuroQol 5 dimensions 5 levels (EQ-5D-5L) 
measurement tool at a 6-month time point (https://www.
improvelto.com/) (10). A number of COVenT participants had 
also participated in the Improve Long-Term Outcome project, 
and so agreement was readily reached that it was appropriate 
for the COVenT COS.
At the end of stage I, three outcomes (survival, pulmonary 
complications, and delirium) reached inclusion criteria for the 
COS by one or more consensus groups, but as they were not 
universally agreed by all groups, they were excluded from the 
COS. Nevertheless, these outcomes may be captured in other 
ways. For the mortality outcome measure, the COVenT COS 
recommends documenting date and time of randomization 
and death which would enable a survival analysis to be under-
taken. Pulmonary complications can be documented and re-
ported alongside other trial adverse events. Delirium is being 
addressed in a separate COS development study (12); therefore, 
ventilation studies that also want to incorporate standardized 
delirium outcomes could add these, when they become avail-
able, to their trial measures.
A limitation of our study was the low number of patient 
participants, a challenge that has been experienced in other 
COS development studies (27). We planned to recruit from 
ICU support groups, but accessing these proved difficult as 
they are not well established internationally. Given the im-
portance of patient involvement in research (28), we asked 
clinical trials groups and the European Federation of Critical 
Care Nurses associations for contact details of support groups 
in their countries, but received no suggestions highlighting a 
need for more work to encourage patient and carer engage-
ment in research. ICU survivors and family carers in our 
study were recruited from Canada and a U.K. charity (https://
icusteps.org/).
We also experienced challenges in engaging participants 
representing research funding organizations. U.K. funders 
were concerned about the potential for exponential requests to 
participate in Delphi studies due to the growing interest in this 
field of research. However, the role of funding organizations 
in the overall COS development process may be more valu-
able for subsequent promotion and dissemination through 
mandating their use in funding applications. This is the case in 
the United Kingdom, where the National Institute for Health 
TABLE 4. Case Report Form Items
Extubation
 Date/time of randomization; date/time of extubation; date/
time to establishment of natural airway.
Reintubation
 Date/time of planned extubation; date/time of each 
reintubation event.
Duration of mechanical ventilation
 Date/time of randomization; date/time of first successful 
unassisted breathing; date/time of death.
Duration of stay
 Date/time of randomization; date/time patient leaves 
critical care unit; date/time patient leaves hospital; date/
time of death.
Mortality
 Date/time of randomization; dead/alive at day 60; date/
time of death.
Health-related quality of life
 Response for each dimension: mobility, self-care, usual 
activities, pain/discomfort, anxiety/depression. Levels: 
no problems, slight problems, moderate problems, 
severe problems, and extreme problems.
 0–100 visual analog scale.
Clinical Investigation
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Research, Health Technology Assessment guidance documents 
encourage applicants to use established COS among the list of 
outcomes where these are available (29). As a result, it is likely 
that we will see a rising tide of COS development and use in 
future trials.
Moving forward, we plan to disseminate the COS through 
the COVenT participants and their organizations, conference 
presentations, social media, research funders, and relevant 
Cochrane Review Groups. We will monitor the uptake of the 
COVenT COS with a planned cohort study that aims to iden-
tify if participation in the COVenT COS development effects 
uptake by individual researchers over the next decade (16).
CONCLUSIONS
Using rigorous and well-established methods, we reached in-
ternational consensus on the COVenT COS that should be re-
ported in all future trials of interventions designed to modify 
the duration of invasive mechanical ventilation in critical care. 
The set comprises standardized definitions and measures for 
six outcome measures (extubation, reintubation, duration of 
mechanical ventilation, length of stay, HRQOL, and mortality). 
We are confident that by standardizing these outcomes, this 
COS will benefit future research in this field. We recommend 
that trialists and systematic reviewers use this COS to enable 
cross-study comparisons, minimize outcome reporting bias, 
and ensure that their research findings provide information 
deemed important by patients, clinicians, and policy makers.
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